Home

Jason Haas

CIK 1883821 · Chief Financial Officer · last filed 2026-08-14

Jason Haas is a Chief Financial Officer who has filed 22 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for LGND, was dated Aug 14, 2026. Across all open-market trades the lifetime net is −$3.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.6M across reported positions. 10 SEC filings were submitted jointly with LIGAND PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.61M

Companies

3

Total Filings

22

Lifetime Open-Market Net

-$3.59M

Filer Profile

Reported Address
C/O SYROS PHARMACEUTICALS, INC.
35 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140
Related Filers
LIGAND PHARMACEUTICALS INC — 10 joint filings, latest 2026-08-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LGND Director 3,981 $290.07 $1.15M -$3.74M 7 2026-08-14
ODTX Chief Financial Officer 62,908 $23.06 $1.45M $20.0K 1 2026-05-11
Syros Pharmaceuticals, Inc. (SYRS) Delisted Chief Financial Officer 0 $0.00 $0 $132.3K 10 2024-11-20

Recent Filings

22 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-14 LGND Mixed −1,000 -$1.77M EDGAR
2026-08-12 LGND Notice (144) −7,138 -$2.09M EDGAR
2026-06-15 LGND Mixed −2,461 -$1.45M EDGAR
2026-06-12 LGND Notice (144) −6,461 -$1.65M EDGAR
2026-06-09 LGND Grant (A) +836 $0 EDGAR
2026-05-11 ODTX Buy (P) +1,000 $20.0K EDGAR
2025-06-10 LGND Grant (A) +1,209 $0 EDGAR
2024-11-20 Syros Pharmaceuticals, Inc. (SYRS) Delisted Sell (S) −137,803 -$29.0K EDGAR
2024-11-18 — Notice (144) −37,803 -$8.7K EDGAR
2024-11-18 — Notice (144) −100,000 -$20.3K EDGAR
Showing 1–10 of 22
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.